4//SEC Filing
Laliberte Kevin 4
Accession 0001562180-19-004967
CIK 0001685071other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 4:05 PM ET
Size
4.9 KB
Accession
0001562180-19-004967
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-09-25$20.00/sh−3,100$62,000→ 8,457 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan based on a limit price order adopted by the Reporting Person.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001709417
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 4:05 PM ET
- Size
- 4.9 KB